Week In Review: $3.4 Billion Week For China Life Science Deals
Armo Biosciences (Nasdaq: ARMO), a Bay Area immuno-oncology company, agreed to be acquired by Eli Lilly (NYSE: LLY) in a $1.6 billion transaction (see story). Last year, Armo raised $67 million in a 2017 Series C-1 funding from China investors. Four months ago, Armo completed a $128 million IPO at a $500 million valuation. Lilly offered to pay $50 per…